Long-term effect of strontium ranelate treatment on BMD

Journal of Bone and Mineral Research

Volumn 20, Issue 11, 2005, Pages 1901-1904

  Blake, Glen M ^a,b   Fogelman, Ignac ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; ETIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE DENSITOMETRY; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; FEMALE; HIP FRACTURE; HUMAN; LONG TERM EXPOSURE; MALE; MONKEY; NONHUMAN; OSTEOPOROSIS; SPINE FRACTURE; VERTEBRA FRACTURE;

ALGORITHMS; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS; FRACTURES, BONE; HUMANS; MACACA FASCICULARIS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; STRONTIUM; THIOPHENES;

EID: 27444435767     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.050810     Document Type: Editorial

References (19)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
2. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C 2002 Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578.
3. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
4. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344-1352.
5. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster J-Y 2001 Effect of risedronate treatment on hip fracture risk in elderly women. N Engl J Med 344:333-340.
6. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249.
7. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Milak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
8. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel E-M, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster J-Y 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468.
9. Reginster J-Y, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Diaz Curiel M, Sawicki A, Goemarere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822.
10. Marshall JH, Lloyd EL, Rundo J, Liniecki J, Marotti G, Mays CW, Sissons HA, Snyder WS 1973 Alkaline earth metabolism in adult man. A report prepared by a task group of Committee 2 of the International Commission on Radiological Protection (ICRP Publication 20). Health Phys 24:129-221.
11. Sowden EM, Stitch SR 1957 Trace elements in human tissue: Estimation of the concentrations of stable strontium and calcium in human bone. Biochem J 67:104-109.
12. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, Allain P, Tsouderos Y, Meunier PJ 1996 Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt administration (S12911). J Bone Miner Res 11:1302-1311.
13. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomised clinical trial. JAMA 282:637-645.
14. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguezportales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
15. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555.
16. Pors Nielsen S, Slosman D, Sorensen OH, Basse-Cathelinat B, De Casin P, Roux C, Meunier PJ 1999 Influence of strontium on bone mineral density and bone mineral content measurements by dual x-ray absorptiometry. J Clin Densitom 2:371-379.
17. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors Nielsen S, De Vernejoul MC, Roces A, Reginster JY 2002 Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomised placebo controlled trial. J Clin Endocrinol Metab 87:2060-2066.
18. Dahl SG, Allain P, Marie PJ, Mauras Y, Boivin G, Ammann P, Tsouderos Y, Delmas PD, Christiansen C 2001 Incorporation and distribution of strontium in bone. Bone 28:446-453.
19. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.